In CLL, the mechanism might be explained by BCR signaling bypassing BTK upon BCR crosslinking as ibrutinib is not able to properly inhibit Ca2+ mobilization and Erk1/2 phosphorylation when surface IgM levels are high (156). Here, BTK is linked to B-cell chronic lymphocytic leukemia.